Menu Search
Equities

Accolade Inc

4NE1:BER

Accolade Inc

Actions
  • Price (EUR)6.75
  • Today's Change0.150 / 2.27%
  • Shares traded0.00
  • 1 Year change-32.50%
  • Beta--
Data delayed at least 15 minutes, as of May 09 2024 17:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.

  • Revenue in USD (TTM)388.49m
  • Net income in USD-122.73m
  • Incorporated2007
  • Employees2.37k
  • Location
    Accolade Inc660 W. Germantown Pike Suite 500PLYMOUTH MEETING 19462United StatesUSA
  • Phone+1 (610) 834-2989
  • Fax+1 (302) 636-5454
  • Websitehttps://www.accolade.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.